Avidity Biosciences is focused on delivering a new class of targeted RNA therapeutics using its proprietary Antibody Oligonucleotide Conjugates (AOC™) platform, primarily targeting rare muscle diseases
Avidity Biosciences is focused on delivering a new class of targeted RNA therapeutics using its proprietary Antibody Oligonucleotide Conjugates (AOC™) platform, primarily targeting rare muscle diseases.